At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SEEL Seelos Therapeutics Inc.
Market Closed 05-10 16:00:00 EDT
0.2680
-0.0142
-5.03%
盘后0.2810
+0.0130+4.85%
19:40 EDT
High0.2900Low0.2602Vol545.45K
Open0.2900D1 Closing0.2822Amplitude10.56%
Mkt Cap4.45MTradable Cap4.38MTotal Shares16.61M
T/O148.21KT/O Rate3.34%Tradable Shares16.33M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BRIEF-Seelos Therapeutics, On April 30, Announced A Reduction In Its Workforce That Affected About 33% Of Its Current Employees
Reuters  ·  05-04
BRIEF-Seelos Therapeutics, On April 30, Announced A Reduction In Its Workforce That Affected About 33% Of Its Current Employees
Seelos Therapeutics Navigates Financial and Board Changes
TIPRANKS  ·  05-04
Seelos Therapeutics Navigates Financial and Board Changes
Psychedelic drug developers could benefit from NIH funding for chronic pain
seekingalpha  ·  04-30
Psychedelic drug developers could benefit from NIH funding for chronic pain
BRIEF-Seelos Therapeutics Appoints Richard Pascoe Chairman Of Board
Reuters  ·  04-29
BRIEF-Seelos Therapeutics Appoints Richard Pascoe Chairman Of Board
Press Release: Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
Dow Jones  ·  04-29
Press Release: Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results
Benzinga  ·  03-20
Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results
BUZZ-Seelos falls on failed ALS drug study
Reuters  ·  03-19
BUZZ-Seelos falls on failed ALS drug study
Seelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpoints
Dow Jones  ·  03-19
Seelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpoints
Seelos falls as lead drug fails in ALS trial
seekingalpha  ·  03-19
Seelos falls as lead drug fails in ALS trial
UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study
Reuters  ·  03-19
UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study
UPDATE 1-Seelos Therapeutics' ALS treatment fails in mid-stage study
Reuters  ·  03-19
UPDATE 1-Seelos Therapeutics' ALS treatment fails in mid-stage study
Seelos says ALS treatment fails in mid-stage study
Reuters  ·  03-19
Seelos says ALS treatment fails in mid-stage study
BRIEF-Seelos Therapeutics Provides Update On Top-Line Results From Its Amyotrophic Lateral Sclerosis Study With SLS-005 (IV Trehalose)
Reuters  ·  03-19
BRIEF-Seelos Therapeutics Provides Update On Top-Line Results From Its Amyotrophic Lateral Sclerosis Study With SLS-005 (IV Trehalose)
Seelos Therapeutics files for 3.4M shares secondary offering
seekingalpha  ·  03-18
Seelos Therapeutics files for 3.4M shares secondary offering
BRIEF-Seelos Therapeutics Inc Files For Common Stock Offering Of Up To 3.4 Million Shares By Selling Stockholders- SEC Filing
Reuters  ·  03-16
BRIEF-Seelos Therapeutics Inc Files For Common Stock Offering Of Up To 3.4 Million Shares By Selling Stockholders- SEC Filing
Psychedelic stocks gain after FDA priority review for MDMA therapy
seekingalpha  ·  02-13
Psychedelic stocks gain after FDA priority review for MDMA therapy
Seelos Therapeutics Issues Common Warrants to Investors
TIPRANKS  ·  01-31
Seelos Therapeutics Issues Common Warrants to Investors
Seelos Therapeutics Strikes $4M Direct Offering Deal
TIPRANKS  ·  01-31
Seelos Therapeutics Strikes $4M Direct Offering Deal
BRIEF-Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering And Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Reuters  ·  01-27
BRIEF-Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering And Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Introduction

Company Name.
Seelos Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
Issue price:
--